Suvratoxumab

N/A

Report date: 2025/03/26 20:01:25

Base Information

Drug NameSuvratoxumab
Drug Alias NameMEDI-4893AR-320
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsAlpha-hemolysin inhibitors
TargetsAlpha-hemolysin
Therapy Area/IndicationsPneumonia, Ventilator-AssociatedPneumonia, StaphylococcalStaphylococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcRegeneron Pharmaceuticals IncBiosynexus Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune LlcAridis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPneumonia, Ventilator-AssociatedPneumonia, StaphylococcalStaphylococcal Infections

Other Information

ATC CodeN/A
Related LinksN/A